Elbe Kliniken Stade-Buxtehude Elbe Klinikum Buxtehude gGmbH — Clinical Trial Site

37 Registered trials

11 Currently recruiting

Organisation

Elbe Kliniken Stade-Buxtehude Elbe Klinikum Buxtehude gGmbH

Location

Buxtehude, Germany

Identifier

ORG-100025859

Address

Am Krankenhaus 1, 21614, Germany

Departments

1006: Klinik für Dermatologie
2169: Klinik fuer Dermatologie
3120: Klinik für Dermatologie
9182: Klinik für Dermatologie
Department of Dermatology
Derma Studien
Dermato- Onkologie
Dermato-Onkologie
Dermato-Onkology
Dermatologie
Dermatologisches Zentrum
Dermatology
Hautklinik
Hautkrebszentrum
Hautkrebszentrum Buxtehude
Klinik fur Dermatologie
Klinik für Dermatologie Hautkrebszentrum Buxtehude Dermatologisches Zentrum
N/A
NA
Sektion Dermatologische Onkologie

Clinical trials at this site (37)

Search interface

Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 High-risk Resected Melanoma 5
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moder… Pending

2023-508329-28-00 Atopic Dermatitis 4
A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag… Recruiting

2023-503630-44-00 Treatment of moderate-to-severe Atopic dermatitis 10 2024-11-20
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4… Recruiting

2022-502825-17-00 Melanoma 4 2024-10-07
Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting

2025-522583-32-00 Cold-Induced Urticaria and Symptomatic Dermographism 5 2026-04-13
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting

2023-504863-17-00 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic 5 2024-02-21
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag… Recruiting

2022-503133-54-00 Solid Tumors 7 2023-08-09
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Recruiting

2023-505634-94-00 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneo 10 2023-02-02
A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o… Recruiting

2024-516331-27-00 Participants with BRAF and/or NRAS mutation positive tu 3 2022-06-10
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513282-39-00 Hidradenitis Suppurativa (HS) 5 2025-05-28
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Prurigo Nodularis 5 2024-12-17
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended

2023-505739-12-01 Chronic Inducible Urticaria (CINDU) 5 2024-09-30
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihis… Ended

2023-505446-25-00 Chronic Spontaneous Urticaria 9 2024-03-20
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch… Ended

2022-502354-14-00 Completely resected Stage IIb/c melanoma 5 2019-10-28
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended

2022-501966-23-00 Resected High-Risk Stage II Melanoma 5 2018-09-11